1037.3000 -10.55 (-1.01%)
NSE Sep 19, 2025 15:57 PM
Volume: 1.1M
 

1037.30
-1.01%
Motilal Oswal
26 May 2017 Cadilas (CDH) 4QFY18 revenue increased significantly by 31% YoY to INR32.5b (est. Gross margin improved ~410bp YoY to 66.7% (65.5% in 3QFY18). EBITDA rose ~88% YoY to INR8.7b (est. of INR7.3b), with margin expansion of ~810bp YoY to 26.8%. Improvement in the gross margin, along with a decrease in employee cost by ~100bp (as % of sales) and in R&D; cost by ~340bp, led to overall margin improvement. Strong revenue growth, coupled with better margins, led to robust ~57% YoY growth in PAT to INR6.1b (est.
Zydus Lifesciences Ltd. is trading above all available SMAs
More from Zydus Lifesciences Ltd.
Recommended